ghrp-2 (EN)

Draft · focused evidence review · clinical sign-off pending · not publicly published

What do the appetite studies actually show?

GHRP-2, also called pralmorelin, stimulates growth-hormone release through the ghrelin receptor. Its endocrine research is most informative when diagnostic testing is kept separate from repeated wellness use.

A measurable response during testing does not establish a benefit from chronic stimulation.

Evidence: Small, short controlled human experiments

Jurisdiction: Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.

A short peptide with several hormonal effects

GHRP-2 is a synthetic hexapeptide: a chain of six amino acids. It acts at the growth hormone secretagogue receptor. Growth hormone is an important response, but this signalling system also interacts with appetite and other hormonal pathways, so “GH releasing” is not a complete description.

What a stimulation test measures

A stimulation test asks whether the pituitary can release growth hormone under defined conditions. It can help investigate a suspected endocrine disorder. That is different from asking whether repeated administration improves energy, body composition or recovery in someone without a confirmed deficiency.

Hunger was measured in people

In a 2005 crossover experiment, 7 healthy lean men ate more during GHRP-2 exposure than during saline exposure; GH also rose. A separate controlled study in 19 lean or obese participants found increased food intake, with higher subjective appetite ratings at the higher exposure. This is a measured short-term appetite effect, not merely a plausible mechanism. It does not establish lasting gains in strength, sleep or recovery. [1] [2]

How to read the safety reports

FDA flags immune-reaction and impurity concerns for compounded injectable or nasal GHRP-2. It also describes serious events reported in recipients, including infection, pancreatitis, increased insulin requirements and deaths among critically ill study participants; a causal link was not established. These reports deserve attention without assuming that GHRP-2 caused every event or that findings in critically ill people quantify risk in healthy users. [3]

Why repeated use needs a different assessment

Longer exposure introduces questions about glucose regulation, fluid retention and effects on other hormones, including cortisol and prolactin. A short diagnostic study cannot answer those questions on its own. Showing that the pathway responds does not establish that repeated stimulation improves health.

Encyclopedia / Lexikon

What / Einordnung

GHRP-2, also known as pralmorelin, is a synthetic six-amino-acid growth-hormone-releasing peptide. Its research includes endocrine testing and appetite responses.

Mechanism / Mechanismus

It activates the ghrelin receptor, also called the growth hormone secretagogue receptor, and stimulates pituitary GH release. The pathway also interacts with appetite and other hormones.

Hunger was measured in people

In a 2005 crossover experiment, 7 healthy lean men ate more during GHRP-2 exposure than during saline exposure; GH also rose. A separate controlled study in 19 lean or obese participants found increased food intake, with higher subjective appetite ratings at the higher exposure. This is a measured short-term appetite effect, not merely a plausible mechanism. It does not establish lasting gains in strength, sleep or recovery. [1] [2]

Controlled acute human experiments; self-rated appetite is distinct from long-term benefit.

Safety / Sicherheit

Repeated exposure raises questions about fluid retention, glucose control, cortisol and prolactin. Short stimulation tests do not define the long-term risk profile.

FDA flags immune-reaction and impurity concerns for compounded injectable or nasal GHRP-2. It also describes serious events reported in recipients, including infection, pancreatitis, increased insulin requirements and deaths among critically ill study participants; a causal link was not established. These reports deserve attention without assuming that GHRP-2 caused every event or that findings in critically ill people quantify risk in healthy users. [3]

FAQ

What does a GH stimulation test measure?

It measures whether the pituitary releases growth hormone in response to a defined stimulus; it does not measure a general rejuvenation effect.

Does a larger GH rise mean greater benefit?

No. Clinical benefits such as strength or symptom relief must be measured directly.

Sources / Quellen

[1] Laferrère et al. (2005): GHRP-2 increases food intake in healthy men — Primary research. PubMed abstract checked; full paper not reviewed; checked 2026-10-29

[2] Laferrère et al. (2006): GHRP-2, food intake and appetite in lean and obese subjects — Primary research. PubMed abstract checked; full paper not reviewed; checked 2026-10-29

[3] FDA: Compounding substances with potential significant safety risks — US regulator. Relevant compound entries checked; not an EU/Swiss authorisation assessment; checked 2026-10-29